{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:06:22Z","timestamp":1787508382527,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014480","name":"Horizon Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005630","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Cardiologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005630","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jbspin.2020.05.001","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T17:22:53Z","timestamp":1589563373000},"page":"387-393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1087-7768","authenticated-orcid":false,"given":"Augustin","family":"Latourte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Pascart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9-Marc","family":"Flipo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Chal\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Coblentz-Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1055-2231","authenticated-orcid":false,"given":"Alain","family":"Cohen-Solal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang-Korng","family":"Ea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Grichy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Letavernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4419-0726","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Liot\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Ottaviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sigwalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Vandecandelaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2132-4074","authenticated-orcid":false,"given":"Pascal","family":"Richette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5080-4790","authenticated-orcid":false,"given":"Thomas","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2020.05.001_bib0295","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/acr.22660","article-title":"Prevalence of Gout in the Adult Population of France","volume":"68","author":"Bardin","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0300","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0305","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","article-title":"Gout","volume":"388","author":"Dalbeth","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0310","first-page":"27","article-title":"Gout: state of the art after a decade of developments","volume":"58","author":"Pascart","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0315","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","article-title":"Gout: why is this curable disease so seldom cured?","volume":"71","author":"Doherty","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0320","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0325","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jbspin.2017.04.002","article-title":"GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century - comparison with 2006 EULAR Recommendations","volume":"84","author":"Goossens","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0330","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":"Prevalence of contraindications and prescription of pharmacologic therapies for gout","volume":"124","author":"Keenan","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0335","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/annrheumdis-2011-200801","article-title":"Patient and provider barriers to effective management of gout in general practice: a qualitative study","volume":"71","author":"Spencer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0340","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3899\/jrheum.150607","article-title":"Barriers to Care in Gout: From Prescriber to Patient","volume":"43","author":"Vaccher","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0345","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0350","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0355","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/acr.22585","article-title":"Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout","volume":"67","author":"Taylor","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0360","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2008.08.006","article-title":"Colchicine update: 2008","volume":"38","author":"Terkeltaub","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0365","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","article-title":"Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options","volume":"15","author":"Bardin","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0370","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","article-title":"Comorbidities in patients with gout prior to and following diagnosis: case-control study","volume":"75","author":"Kuo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0375","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/rheumatology\/keu157","article-title":"Prophylaxis for acute gout flares after initiation of urate-lowering therapy","volume":"53","author":"Latourte","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0385","first-page":"331","article-title":"Local ice therapy during bouts of acute gouty arthritis","volume":"29","author":"Schlesinger","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0390","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13075-019-1965-0","article-title":"Local ice cryotherapy decreases synovial interleukin 6, interleukin 1beta, vascular endothelial growth factor, prostaglandin-E2, and nuclear factor kappa B p65 in human knee arthritis: a controlled study","volume":"21","author":"Guillot","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0395","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1445-5994.1987.tb01232.x","article-title":"Does colchicine work? The results of the first controlled study in acute gout","volume":"17","author":"Ahern","year":"1987","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0400","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0405","first-page":"255","article-title":"Diversity of opinions on the management of gout in France. A survey of 750 rheumatologists","volume":"63","author":"Rozenberg","year":"1996","journal-title":"Rev Rhum Engl Ed"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0410","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/annrheumdis-2019-216154","article-title":"Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care","volume":"79","author":"Roddy","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0415","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/15563650.2010.495348","article-title":"Colchicine poisoning: the dark side of an ancient drug","volume":"48","author":"Finkelstein","year":"2010","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0420","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/kex453","article-title":"Update on colchicine, 2017","volume":"57","author":"Slobodnick","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0425","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.30389","article-title":"Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/P-glycoprotein inhibitors","volume":"63","author":"Terkeltaub","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0430","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40261-014-0238-6","article-title":"Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease","volume":"34","author":"Wason","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0435","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.annemergmed.2006.11.014","article-title":"Comparison of oral prednisolone\/paracetamol and oral indomethacin\/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial","volume":"49","author":"Man","year":"2007","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0440","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/M14-2070","article-title":"Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial","volume":"164","author":"Rainer","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0445","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","article-title":"Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial","volume":"371","author":"Janssens","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0450","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(08)61548-2","article-title":"Should prednisolone be first-line therapy for acute gout?","volume":"372","author":"Richette","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0455","first-page":"2285","article-title":"Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide","volume":"26","author":"Fernandez","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0460","first-page":"CD010120","article-title":"Non-steroidal anti-inflammatory drugs for acute gout","volume":"16","author":"van Durme","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0465","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Coxib","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0470","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0475","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0480","doi-asserted-by":"crossref","first-page":"j1909","DOI":"10.1136\/bmj.j1909","article-title":"Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data","volume":"357","author":"Bally","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0485","doi-asserted-by":"crossref","first-page":"k3426","DOI":"10.1136\/bmj.k3426","article-title":"Diclofenac use and cardiovascular risks: series of nationwide cohort studies","volume":"362","author":"Schmidt","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0490","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0495","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0500","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/key402","article-title":"Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial","volume":"58","author":"Janssen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0505","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.semarthrit.2010.03.001","article-title":"Anakinra's efficacy is variable in refractory gout: report of ten cases","volume":"40","author":"Chen","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0510","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/acr.21989","article-title":"Treatment of acute gouty arthritis in complex hospitalized patients with anakinra","volume":"65","author":"Ghosh","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0515","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/ar4303","article-title":"Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases","volume":"15","author":"Ottaviani","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0520","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0525","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jbspin.2018.03.015","article-title":"Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study","volume":"85","author":"Loustau","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0535","first-page":"104","article-title":"Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study","volume":"33","author":"Neogi","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0540","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jbspin.2015.10.006","article-title":"GOSPEL 2 - Colchicine for the treatment of gout flares in France - a GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age","volume":"83","author":"Pascart","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0545","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1001\/jama.2014.14484","article-title":"Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England","volume":"312","author":"Kuo","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0550","first-page":"630","article-title":"Characteristics and management of gout patients in Europe: data from a large cohort of patients","volume":"19","author":"Richette","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0555","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jbspin.2018.08.006","article-title":"Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: a process based on literature reviews and expert consensus","volume":"86","author":"Gossec","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0560","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/annrheumdis-2014-206807","article-title":"EULAR recommendations for patient education for people with inflammatory arthritis","volume":"74","author":"Zangi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0565","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/annrheumdis-2013-203779","article-title":"Revisiting comorbidities in gout: a cluster analysis","volume":"74","author":"Richette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0575","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13075-019-2027-3","article-title":"IL1 inhibition in gout-where are we a decade on?","volume":"21","author":"So","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2020.05.001_bib0580","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X20300841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X20300841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:26:05Z","timestamp":1761150365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X20300841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1297319X20300841"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2020.05.001","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2020.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}]}}